newsfilter
← Latest News
GlobeNewswire·

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase